Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EBITDA (2016 - 2026)

Anika Therapeutics has reported EBITDA over the past 17 years, most recently at -$5.4 million for Q1 2026.

  • Quarterly EBITDA fell 28.95% to -$5.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$10.3 million through Mar 2026, up 81.83% year-over-year, with the annual reading at -$9.1 million for FY2025, 84.17% up from the prior year.
  • EBITDA was -$5.4 million for Q1 2026 at Anika Therapeutics, down from $272000.0 in the prior quarter.
  • Over five years, EBITDA peaked at $272000.0 in Q4 2025 and troughed at -$62.4 million in Q4 2023.
  • The 5-year median for EBITDA is -$4.2 million (2025), against an average of -$10.0 million.
  • Year-over-year, EBITDA plummeted 1518.55% in 2023 and then surged 101.19% in 2025.
  • A 5-year view of EBITDA shows it stood at -$3.9 million in 2022, then plummeted by 1518.55% to -$62.4 million in 2023, then skyrocketed by 63.21% to -$22.9 million in 2024, then surged by 101.19% to $272000.0 in 2025, then plummeted by 2087.87% to -$5.4 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's EBITDA are -$5.4 million (Q1 2026), $272000.0 (Q4 2025), and -$2.5 million (Q3 2025).